Physician profile
Esther Chaim
NPI 1063450062
$1,474.60
in general payments reported to CMS, 2019-2025
13 companies · $413 in 2025
The $413 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $25.10 · 2020: $14.21 · 2021: $108 · 2022: $98.31 · 2023: $142 · 2024: $674 · 2025: $413.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,229.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,229.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $325.34 | 2020-2025 | Airsupra, Farxiga, Breztri |
| Amgen INC. | $289.13 | 2022-2025 | Repatha, Otezla, Otezla |
| Abbvie INC. | $218.38 | 2021-2025 | Qulipta |
| Glaxosmithkline, LLC. | $171.04 | 2024-2025 | Trelegy Ellipta |
| Horizon Therapeutics Plc | $113.03 | 2021-2022 | |
| Novo Nordisk INC | $88.34 | 2024 | Ozempic, Rybelsus |
| Aimmune Therapeutics, INC. | $73.71 | 2024-2025 | Zenpep |
| Pfizer INC. | $65.71 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $30.90 | 2021-2022 | |
| Azurity Pharmaceuticals, INC. | $27.45 | 2024 | Edarbi |
| Kowa Pharmaceuticals America, INC. | $27.42 | 2024 | Livalo |
| Merck Sharp & Dohme LLC | $25.10 | 2019 | |
| Nestle Healthcare Nutrition INC. | $19.05 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Esther Chaim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.